- Home
- CHY vs OPT Comparison
CHY vs OPT Comparison
Compare CHY & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- OPT
- Stock Information
- Founded
- CHY 2003
- OPT 1984
- Country
- CHY United States
- OPT Australia
- Employees
- CHY N/A
- OPT N/A
- Industry
- CHY Investment Managers
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHY Finance
- OPT Health Care
- Exchange
- CHY Nasdaq
- OPT Nasdaq
- Market Cap
- CHY 934.9M
- OPT 855.6M
- IPO Year
- CHY N/A
- OPT 2020
- Fundamental
- Price
- CHY $11.06
- OPT $5.09
- Analyst Decision
- CHY
- OPT Strong Buy
- Analyst Count
- CHY 0
- OPT 1
- Target Price
- CHY N/A
- OPT $12.00
- AVG Volume (30 Days)
- CHY 128.3K
- OPT 40.1K
- Earning Date
- CHY 01-01-0001
- OPT 03-03-2025
- Dividend Yield
- CHY 10.11%
- OPT N/A
- EPS Growth
- CHY N/A
- OPT N/A
- EPS
- CHY N/A
- OPT N/A
- Revenue
- CHY N/A
- OPT $261,859.00
- Revenue This Year
- CHY N/A
- OPT N/A
- Revenue Next Year
- CHY N/A
- OPT $46,864.26
- P/E Ratio
- CHY N/A
- OPT N/A
- Revenue Growth
- CHY N/A
- OPT N/A
- 52 Week Low
- CHY $9.97
- OPT $1.79
- 52 Week High
- CHY $12.16
- OPT $6.30
- Technical
- Relative Strength Index (RSI)
- CHY 30.00
- OPT 53.99
- Support Level
- CHY $11.26
- OPT $4.77
- Resistance Level
- CHY $11.43
- OPT $5.46
- Average True Range (ATR)
- CHY 0.12
- OPT 0.32
- MACD
- CHY -0.00
- OPT -0.11
- Stochastic Oscillator
- CHY 4.06
- OPT 20.60
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.